ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TAXOL
Breast cancer
Gynecologic cancers
Kaposi's sarcoma
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TAXOL Rx

Generic Name and Formulations:
Paclitaxel 6mg/mL; soln for IV infusion after dilution; contains polyoxyl 35 castor oil, dehydrated alcohol.

Company:
Bristol-Myers Squibb

Therapeutic Use:

Indications for TAXOL:

Adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. Breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.

Adult:

See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. Breast cancer (node-positive): 175mg/m2 IV over 3 hours every 3 weeks for 4 courses administered sequentially to doxorubicin-containing combination chemotherapy. Breast cancer (after failure of initial chemotherapy for metastatic disease or relapse): 175mg/m2 IV over 3 hours every 3 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,500cells/mm3 or platelets <100,000cells/mm3.

Children:

Not established.

Contraindications:

Baseline neutrophil count <1,500cells/mm3.

Boxed Warning:

Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.

Warnings/Precautions:

Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacological Class:

Antimicrotubule agent.

Interactions:

May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.

Adverse Reactions:

Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.

How Supplied:

Multidose vial (5mL, 16.7mL, 50mL)—1


Data provided by MPR.

Indications for TAXOL:

First-line therapy (in combination with cisplatin) and subsequent therapy for advanced carcinoma of the ovary.

Adult:

See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. Previously untreated ovarian cancer: 175mg/m2 IV over 3 hours + cisplatin every 3 weeks; or 135mg/m2 IV over 24 hours + cisplatin every 3 weeks. Previously treated ovarian cancer: 135mg/m2 or 175mg/m2 IV over 3 hours every 3 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,500cells/mm3 or platelets <100,000cells/mm3.

Children:

Not established.

Contraindications:

Baseline neutrophil count <1,500cells/mm3.

Boxed Warning:

Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.

Warnings/Precautions:

Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacological Class:

Antimicrotubule agent.

Interactions:

May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.

Adverse Reactions:

Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.

How Supplied:

Multidose vial (5mL, 16.7mL, 50mL)—1


Data provided by MPR.

Indications for TAXOL:

Second-line treatment of AIDS-related Kaposi's sarcoma.

Adult:

See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. 135mg/m2 IV over 3 hours every 3 weeks; or 100mg/m2 IV over 3 hours every 2 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,000cells/mm3 or platelets <100,000cells/mm3.

Children:

Not established.

Contraindications:

Baseline neutrophil count <1,000cells/mm3.

Boxed Warning:

Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.

Warnings/Precautions:

Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacological Class:

Antimicrotubule agent.

Interactions:

May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.

Adverse Reactions:

Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.

How Supplied:

Multidose vial (5mL, 16.7mL, 50mL)—1


Data provided by MPR.

Indications for TAXOL:

First-line treatment of non-small cell lung cancer in combination with cisplatin in patients who are not candidates for potentially curative surgery and/or radiation therapy.

Adult:

See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. 135mg/m2 IV over 24 hours + cisplatin every 3 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,500cells/mm3 or platelets <100,000cells/mm3.

Children:

Not established.

Contraindications:

Baseline neutrophil count <1,500cells/mm3.

Boxed Warning:

Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.

Warnings/Precautions:

Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacological Class:

Antimicrotubule agent.

Interactions:

May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.

Adverse Reactions:

Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.

How Supplied:

Multidose vial (5mL, 16.7mL, 50mL)—1


Data provided by MPR.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs